← All Grace Therapeutics, INC filings

Grace Therapeutics, INC 8-K filings

NASDAQ
GRCE
Grace Therapeutics, INC
8-K: Acasti Pharma Reports Year-End Results, GTX-104 Trial On Track for 2025 NDA Submission
Acasti Pharma announced its fiscal year 2024 financial results and provided a business update, highlighting the progress of its GTX-104 clinical trial and a projected cash runway into the second quarter of 2026.
NASDAQ
GRCE
Grace Therapeutics, INC
8-K: Acasti Pharma Advances GTX-104 for Brain Hemorrhage Treatment, Targeting $300M US Market
Acasti Pharma is developing GTX-104, an intravenous nimodipine formulation, to address the limitations of oral nimodipine in treating aneurysmal subarachnoid hemorrhage (aSAH), with a Phase 3 trial underway and a potential NDA submission in 2025.
NASDAQ
GRCE
Grace Therapeutics, INC
8-K: Acasti Pharma Reports Q3 2024 Financial Results and Provides Business Update
Acasti Pharma announced its third fiscal quarter 2024 results, highlighting progress with its GTX-104 clinical trial and an extended cash runway into the second quarter of 2026.